AR085483A1 - TREATMENT OF ATTENTION DEFICIT DISEASE WITH HYPERACTIVITY, TREATMENT METHOD, PHARMACEUTICAL COMBINATION - Google Patents

TREATMENT OF ATTENTION DEFICIT DISEASE WITH HYPERACTIVITY, TREATMENT METHOD, PHARMACEUTICAL COMBINATION

Info

Publication number
AR085483A1
AR085483A1 ARP120100944A ARP120100944A AR085483A1 AR 085483 A1 AR085483 A1 AR 085483A1 AR P120100944 A ARP120100944 A AR P120100944A AR P120100944 A ARP120100944 A AR P120100944A AR 085483 A1 AR085483 A1 AR 085483A1
Authority
AR
Argentina
Prior art keywords
treatment
hyperactivity
azabicyclo
benzofuran
pyridinyl
Prior art date
Application number
ARP120100944A
Other languages
Spanish (es)
Inventor
Merouane Bencherif
Terry Hauser
Geoffrey Charles Dunbar
David A Hosford
Gregory J Gatto
Kristen Jordan
Anthony Carl Segreti
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of AR085483A1 publication Critical patent/AR085483A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Un método de tratamiento de TDAH, caracterizado porque comprende administrar una cantidad terapéuticamente eficaz de (2S,3R)-N-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida o una sal farmacéuticamente aceptable de ella.Reivindicación 16: Una combinación de (2S,3R)-N-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida o una sal farmacéuticamente aceptable de ella, u otro agonista de a7, con uno o más agentes estimulantes, uno o más agentes antidepresivos y uno o más agentes antihipertensivos para tratar el TDAH del tipo combinado, desatento o hiperactivo/impulsivo. Reivindicación 17: Una combinación de (2S,3R)-N-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2loct-3-il)benzofuran-2-carboxamida o una sal farmacéuticamente aceptable de ella con otro agente terapéutico para tratar el TDAH.Claim 1: An ADHD treatment method, characterized in that it comprises administering a therapeutically effective amount of (2S, 3R) -N- (2 - ((3-pyridinyl) methyl) -1-azabicyclo [2.2.2] oct-3 -yl) benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof. Claim 16: A combination of (2S, 3R) -N- (2 - ((3-pyridinyl) methyl) -1-azabicyclo [2.2.2] oct-3-yl) benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof, or other a7 agonist, with one or more stimulating agents, one or more antidepressant agents and one or more antihypertensive agents for treating ADHD of the combined type , inattentive or hyperactive / impulsive. Claim 17: A combination of (2S, 3R) -N- (2 - ((3-pyridinyl) methyl) -1-azabicyclo [2.2.2loct-3-yl) benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof with another therapeutic agent to treat ADHD.

ARP120100944A 2011-03-23 2012-03-22 TREATMENT OF ATTENTION DEFICIT DISEASE WITH HYPERACTIVITY, TREATMENT METHOD, PHARMACEUTICAL COMBINATION AR085483A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161466644P 2011-03-23 2011-03-23
US201161489740P 2011-05-25 2011-05-25
US201161510092P 2011-07-21 2011-07-21

Publications (1)

Publication Number Publication Date
AR085483A1 true AR085483A1 (en) 2013-10-02

Family

ID=45922840

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100944A AR085483A1 (en) 2011-03-23 2012-03-22 TREATMENT OF ATTENTION DEFICIT DISEASE WITH HYPERACTIVITY, TREATMENT METHOD, PHARMACEUTICAL COMBINATION

Country Status (3)

Country Link
AR (1) AR085483A1 (en)
TW (1) TW201244717A (en)
WO (1) WO2012129262A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103896826B (en) * 2012-12-26 2016-08-03 上海朴颐化学科技有限公司 The method of asymmetric synthesis of (3R, 4R)-3-methylamino-4-methyl piperidine of nitrogen protection, relevant intermediate and method for preparing raw material

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab 3 - pyridyloxy (or thio) alkyl heterocyclic compounds, pharmaceutical compositions containing them and their uses in the preparation of medicaments for controlling chemical synaptic transmission
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
SA08290475B1 (en) 2007-08-02 2013-06-22 Targacept Inc (2S,3R)-N-(2-((3-Pyridinyl)Methyl)-1-Azabicyclo[2.2.2]Oct-3-yl)Benzofuran-2-Carboxamide, Novel Salt forms, and Methods of Use Thereof

Also Published As

Publication number Publication date
WO2012129262A1 (en) 2012-09-27
TW201244717A (en) 2012-11-16

Similar Documents

Publication Publication Date Title
AR121843A2 (en) OPHTHALMIC FORMULATION AND METHOD TO IMPROVE PRESBYOPIA
NI201100147A (en) METHODS TO TREAT ACUTE MYOCARDIAL INFARCTIONS AND RELATED DISORDERS.
MY189333A (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
BR112015006828A2 (en) compound, or a pharmaceutically acceptable salt thereof; pharmaceutical composition; method for treating a disease in a patient in need of treatment; and method for modulating the activity of an ire1 protein
MX2021000071A (en) Use of pridopidine to improve cognitive function and for treating alzheimer's disease.
AR109103A1 (en) TREATMENT OF FABRY'S DISEASE IN PATIENTS NOT TREATED AND PREVIOUSLY TREATED WITH ERT
RS54707B1 (en) Treatment of crohn's disease with laquinimod
BR112015006341A2 (en) compounds, pharmaceutical composition, method for treating fibrotic condition, therapeutically effective amount of compound, pharmaceutically acceptable salt thereof or pharmaceutical composition and uses thereof and of compounds and / or pharmaceutical composition
NZ630589A (en) Methods of treating alzheimer’s disease and pharmaceutical compositions thereof
GEP201706786B (en) Methods and drug products for treating alzheimer's disease
AR079552A1 (en) METHOD FOR THE TREATMENT OF ATRIAL FIBRILATION. PHARMACEUTICAL FORMULATION
IN2015DN00376A (en)
BR112012022064A2 (en) treatment of lupus arthritis using laquinimod
EA201490254A1 (en) COMBINED TREATMENT OF HEPATITIS C
BR112012007829A2 (en) method for treating overactive bladder; and, pharmaceutical composition.
MX2018013973A (en) Methods of treating behavioral syndromes using pipradrol.
MX2013008715A (en) Use of (s) - esmolol for controlling venous irritation associated with the treatment of a cardiac disorder.
AR100369A1 (en) COMPOSITION OF FIXED DOSE OF FORMOTEROL AND BUDESONIDE
BR112014010729A2 (en) methods for treating gout attacks
CO7170176A2 (en) New compound that has the ability to inhibit the enzyme dehydrogenase11b-hydroxysteroid type 1 (11b-hsd1) or pharmaceutically acceptable salt thereof, method of producing the same, and pharmaceutical composition containing the same as active ingredient
AR091724A1 (en) TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND FAMPRIDINE, PHARMACEUTICAL COMPOSITION
EA201691656A2 (en) THERAPEUTIC WAYS WITH THE USE OF NORIBOGOGINE AND RELATED COMPOUNDS
BR112014012054A2 (en) deferiprone treatment methods
BR112013018296A2 (en) treatment of cognitive dysfunctions in schizophrenia
CL2011000805A1 (en) Use of dabigatran etexilate or a salt thereof to prepare a useful medication for the prevention of stroke in patients suffering from atrial fibrillation.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal